A new in-depth analysis suggests that popular glucagon-like peptide 1 (GLP-1) drugs such as semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) can lower appetite so much that some people may not get enough key nutrients, especially when diet support is missing.
Sign up to view the results!
Continue with Facebook
Continue with your email
The findings matter because GLP-1 medications are increasingly used for long-term diabetes management and overall health, and nutrition gaps can affect energy levels, muscle mass, and bone strength.
GLP-1 drugs are part of a group of medications called incretin therapies. They were first developed to help manage blood sugar in people living with type 2 diabetes and are now also used for weight management.
The main drugs reviewed in the study were semaglutide and tirzepatide. Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two related hormone pathways involved in blood sugar control and appetite regulation.
These medications work by mimicking natural hormones in the body that help regulate blood sugar after meals and reduce appetite. They slow digestion, increase feelings of fullness, and lower hunger and food cravings. For many people, this leads to eating fewer calories, which can affect both blood sugar management and overall nutrition.
Importantly, the prescribing information for these medications states that they are meant to be used in combination with a reduced-calorie diet and increased physical activity, not as stand-alone treatments. Nutrition and movement are considered part of diabetes care with these drugs, not optional add-ons.
The researchers gathered and analyzed all the available studies on this topic to understand patterns and gaps in the evidence. The 12 studies they found varied widely in how much diet guidance people received, ranging from structured meal plans to general advice — and in many cases, no formal nutrition support at all.
Across studies, people taking GLP-1 drugs ate 24 percent to 39 percent fewer calories on average. While calorie reduction is expected, the review found several nutrition-related concerns:
GLP-1 drugs like semaglutide and tirzepatide can be effective tools for managing type 2 diabetes, but this review highlights an important gap: Nutrition support is often missing. Appetite suppression is expected with these medications, but without guidance, some people may not get enough protein, vitamins, or minerals to support energy levels, muscle health, and stable blood sugar.
The researchers suggest that early involvement from a registered dietitian and regular nutrition check-ins could help reduce the risk of nutrient deficiencies, protect muscle mass, and make side effects like nausea or early fullness easier to manage. Because people with diabetes often have different health needs and may take other medications, individualized nutrition support can be especially important.
If you’re taking or considering a GLP-1 medication, it may help to speak with your healthcare provider about nutrition support and whether working with a registered dietitian could be part of your diabetes care plan. These medications are meant to be used alongside healthy eating and physical activity, and the right support may help make treatment safer and more sustainable over time.
On DiabetesTeam, people share their experiences with diabetes, get advice, and find support from others who understand.
Have you received diet support while taking a GLP-1 drug? Let others know in the comments below.
Get updates directly to your inbox.
Continue with Facebook
Continue with your email
Become a member to get even more
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.